uniQure N.V. - Ordinary Shares (QURE): Price and Financial Metrics

uniQure N.V. - Ordinary Shares (QURE)

Today's Latest Price: $36.30 USD

1.95 (-5.10%)

Updated Jan 27 4:00pm

Add QURE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 488 in Biotech

See all "A" rated Strong Buy stocks

QURE Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for QURE is 0.03 -- better than only 10.32% of US stocks.
  • Of note is the ratio of uniQure NV's sales and general administrative expense to its total operating expenses; only 13.03% of US stocks have a lower such ratio.
  • With a price/sales ratio of 281.18, uniQure NV has a higher such ratio than 98.05% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to uniQure NV, a group of peers worth examining would be AUTL, FIXX, CKPT, RAPT, and BBIO.
  • Visit QURE's SEC page to see the company's official filings. To visit the company's web site, go to www.uniqure.com.

QURE Stock Price Chart Interactive Chart >

Price chart for QURE

QURE Price/Volume Stats

Current price $36.30 52-week high $71.45
Prev. close $38.25 52-week low $34.38
Day low $36.05 Volume 486,466
Day high $38.46 Avg. volume 394,588
50-day MA $42.71 Dividend yield N/A
200-day MA $46.52 Market Cap 1.62B

uniQure N.V. - Ordinary Shares (QURE) Company Bio

uniQure is a biopharmaceutical company, developing adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company was founded in 1998 and is based in Amsterdam, the Netherlands.

QURE Latest News Stream

Event/Time News Detail
Loading, please wait...

QURE Latest Social Stream

Loading social stream, please wait...

View Full QURE Social Stream

Latest QURE News From Around the Web

Below are the latest news stories about uniQure NV that investors may wish to consider to help them evaluate QURE as an investment opportunity.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE

NEW YORK, NY / ACCESSWIRE / January 6, 2021 / Pomerantz LLP is investigating claims on behalf of investors of uniQure N.

Yahoo | January 7, 2021

Is QURE A Good Stock To Buy According To Hedge Funds?

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]

Yahoo | December 21, 2020

Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure Dives

Crispr Therapeutics, Editas Medicine and Intellia Therapeutics were ablaze Monday as all three genetics stocks touched highs. Uniqure stock fell on a clinical hold for its gene therapy test.

Yahoo | December 21, 2020

UniQure Hemophilia Therapy Placed on FDA Clinical Hold

The FDA placed a uniQure program on clinical hold due to a safety issue: a possible link to liver cancer.

Yahoo | December 21, 2020

UniQure Plunges As FDA Slaps Clinical Hold On Hemophilia B Gene Therapy Study On Possible Liver Cancer Link

Uniqure NV (NASDAQ: QURE) shares are moving sharply to the downside after the gene therapy company announced a setback to its clinical study.What Happened: Lexington, Massachusetts-based uniQure said the FDA has placed its Hemophilia B gene therapy program, including the late-stage HOPE-B study, on clinical hold.The negative FDA action follows the submission of a safety report in mid-December, which included a serious adverse event of hepatocellular carcinoma - a form of liver cancer - that occurred in a patient in the HOPE B study, who was treated in October 2019. The trial is evaluating uniQure's investigational gene therapy etranacogene dezaparvovec for Hemophilia B.The company clarified that the patient has multiple risk factors associated with HCC, including a 25-year history of h...

Yahoo | December 21, 2020

Read More 'QURE' Stories Here

QURE Price Returns

1-mo -2.02%
3-mo -9.81%
6-mo -13.01%
1-year -40.67%
3-year 87.21%
5-year 99.12%
YTD 0.47%
2020 -49.58%
2019 148.65%
2018 47.12%
2017 249.82%
2016 -66.14%

Continue Researching QURE

Want to see what other sources are saying about uniQure NV's financials and stock price? Try the links below:

uniQure NV (QURE) Stock Price | Nasdaq
uniQure NV (QURE) Stock Quote, History and News - Yahoo Finance
uniQure NV (QURE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8048 seconds.